Hisun and Celsion Corporation (CLN) Sign MOU to Expand ThermoDox® Collaboration
7/23/2013 9:07:35 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
July 22, 2013 -- Zhejiang Hisun Pharma and Celsion Corporation of the US signed a new MOU that expands their collaboration on ThermoDox®, a heat-activated liposomal encapsulation of doxorubicin for primary liver cancer. In June 2012, Celsion and Hisun signed a long-term commercial supply agreement for the production of ThermoDox. The new MOU calls for the two companies to conduct clinical trials of ThemoDox in China, develop new liposomal formulations, and transfer to Hisun the technology allowing commercial manufacture of ThermoDox. More details....
Stock Symbols: (SHA: 600267) (NSDQ: CLSN)
Help employers find you! Check out all the jobs and post your resume.
comments powered by